Abstract 435P
Background
Young adults form an essential component of the country's active population and significantly impact the health-care strategy of the nation. Cancer patterns and biology in this age group differ from those in pediatric and older adults. Cancer in this age group may be due to a combination of environmental and congenital factors or neither of them. It may result from spontaneous mutations to a malignant phenotype unrelated to environmental or inherited factors. The literature is relatively scarce in the context of Indian patients diagnosed with cancer in a younger age group. This study aims at describing the disease profile of these patients in the Indian population.
Methods
The current study is a retrospective analysis of young adult patients of age between 18-39 years registered and treated from January 2018 to September 2021 in the department of Radiation Oncology. The following demographic profile and parameters were assessed: Age, gender, ECOG performance status (PS), addiction and family history, site of primary malignancies, and stage of the disease.
Results
A total of 8588 patients were registered during the study period. Of them, 850 patients ( 10%) were between the ages of 18-39. Maximum (73%) of the patient belonged to the 30-39years age group. Male to female ratios were almost equal. Young male patients were 51.6%, and females were 48.4%. Patients visiting from local region & state were 45.4% whereas from nearby states were 54.5%. 52% of patients presented with good performance score (PS ≤2). Positive family history of malignancy was found in only 3.5%, whereas 24% of the patients gave an addiction history of smoking/tobacco chewing or alcohol. The most commonly observed malignancies were with the head and neck (28%), followed by the breast (22%). Head and neck cancer mainly were observed in males (23.8%), whereas females (20.8%) had higher breast cancer. Table: 435P
Overall stage groupIIIIIIV | 5%14%32%48% |
SitesHead & neckBreastGastrointestinalGenitourinaryCentral nervous systemSarcomaHepatobiliaryLungSkin/others | 28.5%23%9.8%9.6%9.6%8.2%4.8%2.3%2.7% |
Conclusions
Cancer among young adult patients forms a primary concern, especially in developing countries. The incidence of advanced and metastatic disease in this group is alarming. Reinforcement of screening programs in this age group should be a priority.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
NA.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
399P - Role of denosumab as targeted therapy in treatment of unresectable or recurrent cases of giant cell tumor of the bone
Presenter: Anchal Mishra
Session: Poster viewing 06
400P - Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
Presenter: Omid Hamid
Session: Poster viewing 06
401P - A phase Ib study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients (pts) with advanced solid tumors
Presenter: Shunsuke Kondo
Session: Poster viewing 06
402P - Phase I study of selumetinib in Chinese pediatric and adult patients (pts) with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN): Interim results
Presenter: Xiao-Jun Yuan
Session: Poster viewing 06
403P - Gender trend over time of principal investigators within large Australian cancer clinical trials groups
Presenter: Thi Thao Vi Luong
Session: Poster viewing 06
404P - Adolescent & young adult cancers (AYA): Experience from a large rural teaching hospital in South India
Presenter: Vishwapriya Godkhindi
Session: Poster viewing 06
405P - Evaluating medical oncology outcomes (EMOO) in Asia study: Diagnosis, staging, treatment patterns and outcome of patients with lung cancer registered 2017-2019
Presenter: Ross Soo
Session: Poster viewing 06
406P - Adrenal insufficiency induced by immune checkpoint inhibitors: Clinical characteristics of 145 cases
Presenter: kaoru koshiba
Session: Poster viewing 06
407P - A post-marketing surveillance of the real-world safety and effectiveness of avelumab in patients with curatively unresectable Merkel cell carcinoma in Japan
Presenter: Naoya Yamazaki
Session: Poster viewing 06
408P - Machine learning for glioblastoma screening from histopathology whole slide imaging
Presenter: Eva Yi Wah Cheung
Session: Poster viewing 06